32
Views
0
CrossRef citations to date
0
Altmetric
Review Article

An overview on recent approaches for colonic drug delivery systems

ORCID Icon & ORCID Icon
Received 19 Apr 2024, Accepted 28 May 2024, Published online: 20 Jun 2024

References

  • Abdelmegid AM, Abdo FK, Ahmed FE, Kattaia AaA 2019. Therapeutic effect of gold nanoparticles on DSS-induced ulcerative colitis in mice with reference to interleukin-17 expression. Sci Rep. 9(1):10176. doi: 10.1038/s41598-019-46671-1.
  • Aib S, Iqbal K, Khan N, Khalid S, Adnan M, Umair SM, Dar MJ. 2022. pH-sensitive liposomes for colonic co-delivery of mesalazine and curcumin for the treatment of ulcerative colitis. J Drug Delivery Sci Technol. 72:103335. doi: 10.1016/j.jddst.2022.103335.
  • Ajorlou E, Khosroushahi AY. 2016. Trends on polymer- and lipid-based nanostructures for parenteral drug delivery to tumors. Cancer Chemother Pharmacol. 79(2):251–265. doi: 10.1007/s00280-016-3168-6.
  • Alaaeldin E, Refaat H, Saber EA, Aziz NM, Abdel-Maqsoud NMR, Aleem MMaE, Kamel MY, Mady FM. 2023. Co-administration of thymoquinone and propolis in liposomal formulations as a potential approach for treatment of acetic acid-induced ulcerative colitis: physiological and histopathological analysis. AAPS PharmSciTech. 24(7):190. doi: 10.1208/s12249-023-02637-1.
  • Alajami HN, Fouad EA, Ashour AE, Kumar A, Yassin AEB. 2022. Celecoxib-Loaded solid lipid nanoparticles for colon delivery: formulation optimization and in vitro assessment of Anti-Cancer activity. Pharmaceutics. 14(1):131. doi: 10.3390/pharmaceutics14010131.
  • Amidon S, Brown J, Dave VS. 2015. Colon-targeted oral drug delivery systems: design trends and approaches. AAPS PharmSciTech. 16(4):731–741. doi: 10.1208/s12249-015-0350-9.
  • Annaji M, Poudel I, Boddu SHS, Arnold RD, Tiwari AK, Babu RJ. 2021. Resveratrol‐loaded nanomedicines for cancer applications. Cancer Reports. 4(3):e1353. doi: 10.1002/cnr2.1353.
  • Arduino I, Liu Z, Rahikkala A, Figueiredo P, Correia A, Cutrignelli A, Denora N, Santos HA. 2021. Preparation of cetyl palmitate-based PEGylated solid lipid nanoparticles by microfluidic technique. Acta Biomater. 121:566–578. doi: 10.1016/j.actbio.2020.12.024.
  • Arun N, Rishika D, Nagasamy Venkatesh D. 2023. Colorectal cancer current treatments and its novel drug delivery systems. J Med Pharmaceut Allied Sci. 12(1):5588–5595. doi: 10.55522/jmpas.V12I1.4391
  • Awad A, Madla CM, McCoubrey LE, Ferraro F, Gavins FK, Buanz A, Gaisford S, Orlu M, Siepmann F, Siepmann J, et al. 2022. Clinical translation of advanced colonic drug delivery technologies. Adv Drug Deliv Rev. 181:114076. doi: 10.1016/j.addr.2021.114076.
  • Azhar SNaS, Ashari SE, Zainuddin N, Hassan M. 2022. Nanostructured lipid carriers-hydrogels system for drug delivery: nanohybrid technology perspective. Molecules. 27(1):289. doi: 10.3390/molecules27010289.
  • Bharti D, Medicherla K, Pooja D, Kulhari H. 2023. Dendrimer-mediated delivery of anticancer drugs for colon cancer treatment. Pharmaceutics. 15(3):801. doi: 10.3390/pharmaceutics15030801.
  • Bhaskaran, Navya Ajitkumar, Jitta, Srinivas Reddy, Cheruku, SriPragnya, Kumar, Nitesh, Kumar, Lalit, Salwa, (2022). Orally delivered solid lipid nanoparticles of irinotecan coupled with chitosan surface modification to treat colon cancer: preparation, in-vitro and in-vivo evaluations.Int J Biol Macromol, 211, 301–315. doi: 10.1016/j.ijbiomac.2022.05.060.
  • Brayden DJ, Hill TA, Fairlie DP, Maher S, Mrsny R. 2020. Systemic delivery of peptides by the oral route: formulation and medicinal chemistry approaches. Adv Drug Deliv Rev. 157:2–36. doi: 10.1016/j.addr.2020.05.007.
  • Campos FL, De Alcântara Lemos J, Oda CMR, De Oliveira Silva J, Fernandes RS, Miranda SEM, Cavalcante CH, Cassali GD, Townsend DM, Leite EA, et al. 2022. Irinotecan-Loaded polymeric micelles as a promising alternative to enhance antitumor efficacy in colorectal cancer therapy. Polymers (Basel). 14(22):4905. doi: 10.3390/polym14224905.
  • Casati F, Melocchi A, Moutaharrik S, Uboldi M, Foppoli A, Maroni A, Zema L, Neut C, Florence S, Siepmann J, et al. 2020. Injection molded capsules for colon delivery combining time-controlled and enzyme-triggered approaches. Int J Mol Sci. 21(6):1917. doi: 10.3390/ijms21061917.
  • Cavalcante CH, Fernandes RS, De Oliveira Silva J, Oda CMR, Leite EA, Cassali GD, Charlie-Silva I, Fernandes BHV, Ferreira LaM, De Barros ALB. 2021. Doxorubicin-loaded pH-sensitive micelles: a promising alternative to enhance antitumor activity and reduce toxicity. Biomed Pharmacother. 134:111076. doi: 10.1016/j.biopha.2020.111076.
  • Chan RP, Pope DJ, Gilbert AP, Sacra P, Baron JH, Lennard‐Jones JE. 1983. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 28(7):609–615. doi: 10.1007/bf01299921.
  • Crouwel F, Buiter HJC, De Boer NK. 2020. Gut microbiota-driven drug metabolism in inflammatory bowel disease. J Crohn’s Colitis. 15(2):307–315. doi: 10.1093/ecco-jcc/jjaa143.
  • Deng J, Wu Z, Zhao Z, Wu C, Yuan M, Su Z, Wang Y, Wang Z. 2020. Berberine-loaded nanostructured lipid carriers enhance the treatment of ulcerative colitis. Int J Nanomedicine. 15:3937–3951. doi: 10.2147/ijn.s247406.
  • Effinger A, M O'Driscoll C, McAllister M, Fotaki N. 2020. Gastrointestinal diseases and their impact on drug solubility: ulcerative colitis. Eur J Pharm Sci. 152:105458. doi: 10.1016/j.ejps.2020.105458.
  • Effinger A, O'Driscoll CM, McAllister M, Fotaki N. 2021. Predicting budesonide performance in healthy subjects and patients with Crohn’s disease using biorelevant in vitro dissolution testing and PBPK modeling. Eur J Pharm Sci. 157:105617. doi: 10.1016/j.ejps.2020.105617.
  • Elkhodiry MA, Momah CC, Suwaidi SR, Gadalla D, Martins AM, Vitor RF, Husseini GA. 2016. Synergistic nanomedicine: passive, active, and ultrasound-triggered drug delivery in cancer treatment. J Nanosci Nanotechnol. 16(1):1–18. doi: 10.1166/jnn.2016.11124.
  • El-Enin HaA, Alquthami AF, Alwagdani AM, Yousef LM, Albuqami MS, Alharthi MA, Alsaab HO. 2022. Utilizing TPGS for optimizing quercetin nanoemulsion for colon cancer cells inhibition. Colloids and Interfaces. 6(3):49. doi: 10.3390/colloids6030049.
  • England R, Hare JI, Barnes JC, Wilson J, Smith A, Strittmatter N, Kemmitt PD, Waring MJ, Barry ST, Alexander C, et al. 2017. Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers. J Control Release. 247:73–85. doi: 10.1016/j.jconrel.2016.12.034.
  • Escalante P, Quiñones LA, Contreras HR. 2021. Epithelial-mesenchymal transition and microRNAs in colorectal cancer chemoresistance to FOLFOX. Pharmaceutics. 13(1):75. doi: 10.3390/pharmaceutics13010075.
  • González-Domínguez JM, Grasa L, Frontiñán-Rubio J, Abás E, Domínguez-Alfaro A, Mesonero JE, Criado A, Ansón-Casaos A. 2022. Intrinsic and selective activity of functionalized carbon nanotube/nanocellulose platforms against colon cancer cells. Colloids Surf B Biointerfaces. 212:112363. doi: 10.1016/j.colsurfb.2022.112363.
  • Handali S, Moghimipour E, Rezaei M, Ramezani Z, Kouchak M, Amini M, Angali KA, Saremy S, Dorkoosh FA. 2018. A novel 5-fluorouracil targeted delivery to colon cancer using folic acid conjugated liposomes. Biomed Pharmacother. 108:1259–1273. doi: 10.1016/j.biopha.2018.09.128.
  • Hatton GB, Madla CM, Rabbie SC, Basit AW. 2019. Gut reaction: impact of systemic diseases on gastrointestinal physiology and drug absorption. Drug Discov Today. 24(2):417–427. doi: 10.1016/j.drudis.2018.11.009.
  • Homayun B, Kumar A, Nascimento PTH, Choi H. 2018. Macropored microparticles with a core–shell architecture for oral delivery of biopharmaceuticals. Arch Pharm Res. 41(8):848–860. doi: 10.1007/s12272-018-1062-y.
  • Ibaraki H, Hatakeyama N, Arima N, Takeda A, Seta Y, Kanazawa T. 2022. Systemic delivery of siRNA to the colon using peptide modified PEG-PCL polymer micelles for the treatment of ulcerative colitis. Eur J Pharm Biopharm. 170:170–178. doi: 10.1016/j.ejpb.2021.12.009.
  • Jin X, Xia X, Li J, Adu-Frimpong M, Wang X, Wang Q, Wu H, Yu Q, Ji H, Toreniyazov E, et al. 2023. Preparation, characterization, pharmacokinetics and ulcerative colitis treatment of hyperoside-loaded mixed micelles. Drug Deliv Transl Res. 14(5):1370–1388. doi: 10.1007/s13346-023-01470-0.
  • Kaur J, Gulati M, Gowthamarajan K, Vishwas S, Kumar Chellappan D, Gupta G, Dua K, Pandey NK, Kumar B, Singh SK. 2021. Combination therapy of vanillic acid and oxaliplatin co-loaded in polysaccharide based functionalized polymeric micelles could offer effective treatment for colon cancer: a hypothesis. Med Hypotheses. 156:110679. doi: 10.1016/j.mehy.2021.110679.
  • Keshavarz F, Soltanshahi M, Khosravani F, Bakhshiyan F, Ghanbari A, Hassanzadeh S, Amirpour M, Ghalamfarsa G. 2024. Thymol-loaded liposomes effectively induced apoptosis and decreased EGFR expression in colorectal cancer cells. Naunyn-Schmiedeberg’s Arch Pharmacol. Epub ahead of print. doi: 10.1007/s00210-024-02945-8.
  • Khalid S, Salman S, Iqbal K, Rehman FU, Ullah I, Satoskar AR, Khan GM, Dar MJ. 2022. Surfactant free synthesis of cationic nano-vesicles: a safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis. Nanomedicine. 40:102490. doi: 10.1016/j.nano.2021.102490.
  • Khan AA, Piris J, Truelove SC. 1977. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5.
  • Kovochich M, Fung CD, Avanasi R, Madl AK. 2017. Review of techniques and studies characterizing the release of carbon nanotubes from nanocomposites: implications for exposure and human health risk assessment. J Expo Sci Environ Epidemiol. 28(3):203–215. doi: 10.1038/jes.2017.6.
  • Kraisit P. 2019. Impact of hydroxypropyl methylcellulose (hpmc) type and concentration on the swelling and release properties of propranolol hydrochloride matrix tablets usning a simplex centroid design. Int J App Pharm. 11(2):143–151. doi: 10.22159/ijap.2019v11i2.31127.
  • Kulhari H, Pooja D, Singh M, Chauhan AS. 2013. Optimization of carboxylate-terminated poly(amidoamine) dendrimer-mediated cisplatin formulation. Drug Dev Ind Pharm. 41(2):232–238. doi: 10.3109/03639045.2013.858735.
  • Kumar G, Virmani T, Sharma A, Pathak K. 2023. Codelivery of phytochemicals with conventional anticancer drugs in form of nanocarriers. Pharmaceutics. 15(3):889. doi: 10.3390/pharmaceutics15030889.
  • Lemmens G, Van Camp A, Kourula S, Vanuytsel T, Augustijns P. 2021. Drug disposition in the lower gastrointestinal tract: targeting and monitoring. Pharmaceutics. 13(2):161. doi: 10.3390/pharmaceutics13020161.
  • Li C, Xu J, Gan Y, Liang X. 2020. Innovative Irinotecan-Loaded nanomicelles will enter Phase I clinical trial in 2021. The Innovation. 1(3):100057. doi: 10.1016/j.xinn.2020.100057.
  • Li M, Liu J, Shi L, Zhou C, Zou M, Fu D, Yuan Y, Yao C, Zhang L, Qin S, et al. 2023. Gold nanoparticles-embedded ceria with enhanced antioxidant activities for treating inflammatory bowel disease. Bioact Mater. 25:95–106. doi: 10.1016/j.bioactmat.2023.01.015.
  • Li W, Li X, Liu S, Yang W, Fan P, Yang X, Du B, Li Q, Pan Y. 2017. Gold nanoparticles attenuate metastasis by tumor vasculature normalization and epithelial-mesenchymal transition inhibition. Int J Nanomedicine. 12:3509–3520. volume doi: 10.2147/ijn.s128802.
  • Li Z, Liu C, Li C, Wang F, Liu J, Zheng Z, Wu J, Zhang B. 2021. Irinotecan/scFv co-loaded liposomes coaction on tumor cells and CAFs for enhanced colorectal cancer therapy. J Nanobiotechnol. 19(1):421. doi: 10.1186/s12951-021-01172-0.
  • Lu Z, Liu J, Zhao L, Wang C, Shi F, Li Z, Liu X, Miao Z. 2023. Enhancement of oral bioavailability and anti-colitis effect of luteolin-loaded polymer micelles with RA (rosmarinic acid)-SS-mPEG as carrier. Drug Dev Ind Pharm. 49(1):17–29. doi: 10.1080/03639045.2023.2175850.
  • Mager LF, Burkhard R, Pett N, Cooke NCA, Brown K, Ramay HR, Paik SY, Stagg J, Groves RA, Gallo M, et al. 2020. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science. 369(6510):1481–1489. doi: 10.1126/science.abc3421.
  • Major G, Murray K, Singh G, Nowak A, Hoad C, Marciani L, Silos-Santiago A, Kurtz CB, Johnston JM, Gowland P, et al. 2018. Demonstration of differences in colonic volumes, transit, chyme consistency, and response to psyllium between healthy and constipated subjects using magnetic resonance imaging. Neurogastroenterol Motil. 30(9):e13400. doi: 10.1111/nmo.13400.
  • Makeen HA, Mohan S, Al-Kasim MA, Attafi IM, Ahmed RA, Syed NK, Sultan MH, Al-Bratty M, Alhazmi HA, Safhi MM, et al. 2020. Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro. Drug Deliv. 27(1):622–631. doi: 10.1080/10717544.2020.1754526.
  • Mishra R, Ahmad A, Kumar A, Vyawahare A, Raza SS, Khan R. 2020. Lipid-based nanocarrier-mediated targeted delivery of celecoxib attenuate severity of ulcerative colitis. Mater Sci Eng C Mater Biol Appl. 116:111103. doi: 10.1016/j.msec.2020.111103.
  • Mishra RK, Ahmad A, Kumar A, Ali A, Kanika N, Jori C, Tabrez S, Zughaibi TA, Almashjary MN, Raza SS, et al. 2023. Cortisone-loaded stearoyl ascorbic acid based nanostructured lipid carriers alleviate inflammatory changes in DSS-induced colitis. BiomaterialsAdvances. 148:213383. doi: 10.1016/j.bioadv.2023.213383.
  • Misra SK, Pathak K. 2023. Nose-to-Brain targeting via nanoemulsion: significance and evidence. Colloids Interfaces. 7(1):23. doi: 10.3390/colloids7010023.
  • Mohamed JMM, Ahmad F, El-Sherbiny M, Mohaini MaA, Venkatesan K, Alrashdi YBA, Eldesoqui MB, Ibrahim AE, Dawood AF, Ibrahim AM, et al. 2024. Optimization and characterization of quercetin-loaded solid lipid nanoparticles for biomedical application in colorectal cancer. Cancer Nano. 15(1):16. doi: 10.1186/s12645-024-00249-3.
  • Motawea A, Hady WEaE, El-Emam GA. 2022. The protective impact of adapted trimebutine maleate-loaded nanostructured lipid carriers for alleviating the severity of acute colitis. Drug Deliv. 29(1):906–924. doi: 10.1080/10717544.2022.2050847.
  • Moutaharrik S, Maroni A, Melocchi A, Zema L, Foppoli A, Cerea M, Palugan L, Neut C, Siepmann F, Siepmann J, et al. 2021. Oral colon delivery platform based on a novel combination approach: design concept and preliminary evaluation. J Drug Delivery Sci Technol. 66:102919. doi: 10.1016/j.jddst.2021.102919.
  • Nunes SS, Miranda SEM, De Oliveira Silva J, Fernandes RS, De Alcântara Lemos J, De Aguiar Ferreira C, Townsend DM, Cassali GD, Oliveira MC, De Barros ALB. 2021. pH-responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment. Biomed Pharmacother. 144:112317. doi: 10.1016/j.biopha.2021.112317.
  • Oda CMR, De Oliveira Silva J, Fernandes RS, Braga AV, Machado RR, De Matos Coelho M, Cassali GD, Reis DCD, De Barros ALB, Leite EA. 2020. Encapsulating paclitaxel in polymeric nanomicelles increases antitumor activity and prevents peripheral neuropathy. Biomed Pharmacother. 132:110864. doi: 10.1016/j.biopha.2020.110864.
  • Peiris M, Aktar R, Reed DE, Cibert-Goton V, Zdanaviciene A, Halder W, Robinow A, Corke S, Dogra H, Knowles CH, et al. 2021. Decoy bypass for appetite suppression in obese adults: role of synergistic nutrient sensing receptors GPR84 and FFAR4 on colonic endocrine cells. Gut. 71(5):928–937. doi: 10.1136/gutjnl-2020-323219.
  • Perumal S. 2022. Polymer nanoparticles: synthesis and applications. Polymers (Basel). 14(24):5449. doi: 10.3390/polym14245449.
  • Randive DS, Shejawal KP, Bhinge SD, Bhutkar MA, Jadhav NR, Patil SB, Nadaf SJ. 2023. Efficient in vitro oxaliplatin delivery with functionalized single-walled carbon nanotube for enhanced colon cancer treatment. Futur J Pharm Sci. 9(1):91. doi: 10.1186/s43094-023-00543-8.
  • Salve PS. 2011. Development and in vitro evaluation colon targeted drug delivery system using natural gums. Asian J Pharma Res. 1(4):91–101.
  • Santalices I, Gonella A, Torres D, Alonso MJ. 2017. Advances on the formulation of proteins using nanotechnologies. J Drug Delivery Sci Technol. 42:155–180. doi: 10.1016/j.jddst.2017.06.018.
  • Sardou HS, Akhgari A, Mohammadpour AH, Namdar AB, Kamali H, Jafarian AH, Garekani HA, Sadeghi F. 2022. Optimization study of combined enteric and time-dependent polymethacrylates as a coating for colon targeted delivery of 5-ASA pellets in rats with ulcerative colitis. Eur J Pharm Sci. 168:106072. doi: 10.1016/j.ejps.2021.106072.
  • Riley SA. 1998. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut. 42(6):761–763. doi: 10.1136/gut.42.6.761.
  • Shabana S, Hamouda HI, Hamadou AH, Ahmed B, Chi Z, Liu C. 2024. Marine phospholipid nanoliposomes: a promising therapeutic approach for inflammatory bowel disease: preparation, safety, and efficacy evaluation. Colloids Surf B Biointerfaces. 234:113702. doi: 10.1016/j.colsurfb.2023.113702.
  • Shakeel F, Haq N, Al-Dhfyan A, Alanazi FK, Alsarra IA. 2014. Double w/o/w nanoemulsion of 5-fluorouracil for self-nanoemulsifying drug delivery system. J Mol Liq. 200:183–190. doi: 10.1016/j.molliq.2014.10.013.
  • Shakeel F, Haq N, El-Badry M, Alanazi FK, Alsarra IA. 2013. Ultra fine super self-nanoemulsifying drug delivery system (SNEDDS) enhanced solubility and dissolution of indomethacin. J Mol Liq. 180:89–94. doi: 10.1016/j.molliq.2013.01.008.
  • Shejawal KP, Randive DS, Bhinge SD, Bhutkar MA, Wadkar GH, Todkar SS, Mohite SK. 2021. Functionalized carbon nanotube for colon-targeted delivery of isolated lycopene in colorectal cancer: ın vitro cytotoxicity and in vivo roentgenographic study. J Mater Res. 36(24):4894–4907. doi: 10.1557/s43578-021-00431-y.
  • Shi F, Yin W, Adu-Frimpong M, Li X, Xia X, Sun W, Ji H, Toreniyazov E, Qilong W, Cao X, et al. 2023. In-vitro and in-vivo evaluation and anti-colitis activity of esculetin-loaded nanostructured lipid carrier decorated with DSPE-MPEG2000. J Microencapsul. 40(6):442–455. doi: 10.1080/02652048.2023.2215345.
  • Shirodkar RK, Kumar L, Mutalik S, Lewis S. 2019. Solid lipid nanoparticles and nanostructured lipid carriers: emerging lipid based drug delivery systems. Pharm Chem J. 53(5):440–453. doi: 10.1007/s11094-019-02017-9.
  • Singh AP, Biswas A, Shukla A, Maiti P. 2019. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct Target Ther. 4(1):33. doi: 10.1038/s41392-019-0068-3.
  • Sopyan I, Komarudin AD, Huang JA, Sunan IS. 2023. An overview: development of colon drug delivery system and its application and limitations. Int J App Pharm. 15(1):24–30. doi: 10.22159/ijap.2023v15i1.46681.
  • Stillhart C, Vučićević K, Augustijns P, Basit AW, Batchelor H, Flanagan T, Gesquiere I, Greupink R, Keszthelyi D, Koskinen M, et al. 2020. Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review. Eur J Pharm Sci. 147:105280. doi: 10.1016/j.ejps.2020.105280.
  • Tefas LR, Toma I, Sesarman A, Banciu M, Jurj A, Berindan-Neagoe I, Rus L, Stiufiuc R, Tomuta I. 2022. Co-delivery of gemcitabine and salinomycin in PEGylated liposomes for enhanced anticancer efficacy against colorectal cancer. J Liposome Res. 33(3):234–250. doi: 10.1080/08982104.2022.2153139.
  • Testa A, Castiglione F, Nardone OM, Colombo GL. 2017. Adherence in ulcerative colitis: an overview. Patient Prefer Adherence. 11:297–303. doi: 10.2147/ppa.s127039.
  • Thakur CK, Neupane R, Karthikeyan C, Ashby CR, Babu RJ, Boddu SHS, Tiwari AK, Moorthy NSHN. 2022. Lysinated multiwalled carbon nanotubes with carbohydrate ligands as an effective nanocarrier for targeted doxorubicin delivery to breast cancer cells. Molecules. 27(21):7461. doi: 10.3390/molecules27217461.
  • Trivedi HD, Puranik PK. 2017. Colon targeted delivery system (codestm): propitious approach in targeting colon. WJPPS. 6(4):768–789. doi: 10.20959/wjpps20174-8951.
  • Tubic-Grozdanis M, Hilfinger JM, Amidon GL, Kim JS, Kijek P, Staubach P, Langguth P. 2008. Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm Res. 25(7):1591–1600. doi: 10.1007/s11095-007-9519-6.
  • Varum F, Freire AC, Bravo R, Basit AW. 2020b. OPTICORETM, an innovative and accurate colonic targeting technology. Int J Pharm. 583:119372. doi: 10.1016/j.ijpharm.2020.119372.
  • Varum F, Freire AC, Fadda HM, Bravo R, Basit AW. 2020a. A dual pH and microbiota-triggered coating (PhloralTM) for fail-safe colonic drug release. Int J Pharm. 583:119379. doi: 10.1016/j.ijpharm.2020.119379.
  • Wang C, Han Z, Wu Y, Lu X, Tang X, Xiao J, Li N. 2021. Enhancing stability and anti-inflammatory properties of curcumin in ulcerative colitis therapy using liposomes mediated colon-specific drug delivery system. Food Chem Toxicol. 151:112123. doi: 10.1016/j.fct.2021.112123.
  • Wang J, Yadav V, Smart AL, Tajiri S, Basit AW. 2015. Stability of peptide drugs in the colon. Eur J Pharm Sci. 78:31–36. doi: 10.1016/j.ejps.2015.06.018.
  • Wu C, Kuo Y, Hong R, Wu H. 2015. α Enolase–binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancer. Sci Transl Med. 7(290):290ra91. doi: 10.1126/scitranslmed.aaa9391.
  • Xian J, Zhong X, Gu H, Wang X, Li J, Li J, Wu Y, Zhang C, Zhang J. 2021. Colonic delivery of celastrol-loaded layer-by-layer liposomes with pectin/trimethylated chitosan coating to enhance its anti-ulcerative colitis effects. Pharmaceutics. 13(12):2005. doi: 10.3390/pharmaceutics13122005.
  • Xian S, Zhu J, Wang Y, Song H, Wang H. 2023. Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice. Drug Deliv. 30(1):2183821. doi: 10.1080/10717544.2023.2183821.
  • Yadav V, House A, Matiz S, McCoubrey LE, Bettano KA, Bhave L, Wang M, Fan PW, Zhou S, Woodhouse JD, et al. 2022. Ileocolonic-targeted JAK inhibitor: a safer and more effective treatment for inflammatory bowel disease. Pharmaceutics. 14(11):2385. doi: 10.3390/pharmaceutics14112385.
  • Yang C, Merlin D. 2019. Nanoparticle-mediated drug delivery systems for the treatment of ibd: current perspectives. Int J Nanomedicine. 14:8875–8889. doi: 10.2147/ijn.s210315.
  • Zhang M, Merlin D. 2018. Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis. Inflamm Bowel Dis. 24(7):1401–1415. doi: 10.1093/ibd/izy123.
  • Zhao J, Hao S, Chen Y, Ye X, Fang P, Hu H. 2024. Tauroursodeoxycholic acid liposome alleviates DSS-induced ulcerative colitis through restoring intestinal barrier and gut microbiota. Colloids Surf B Biointerfaces. 236:113798. doi: 10.1016/j.colsurfb.2024.113798.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.